# Coverage and effectiveness of mRNA SARS-CoV-2 vaccines among United States Veterans

**Authors:** Yinong Young-Xu, ScD, MA, MS[1,2], Caroline Korves, ScD[1], Ethan I. Powell, BA[1]; Gabrielle M. Zwain, BA[1], and Jeremy Smith, MS[1]

**Author Institutions/Affiliations:**

1. White River Junction Veterans Affairs Medical Center, White River Junction, VT
2. Geisel School of Medicine at Dartmouth, Hanover, NH

**Corresponding Author:**
Yinong Young-Xu
Veterans Affairs Medical Center
215 North Main Street
White River Junction, VT 05009
Yinong.Young-Xu@va.gov

**Acknowledgements of research support for the study:** This project was funded by the United States Food and Drug Administration (FDA) through an interagency agreement with the Veterans Health Administration

**Conflict of Interest Declaration:** The authors acknowledge that Pfizer has given grants for other research.

**Journal:**

**Word count:** 2,891/3,000

**Number of Tables and/or Figures:** 5 Tables

**Key words:** COVID-19; mRNA vaccine; SARS-CoV-2; Veterans; vaccine effectiveness

**Key Points (limit 75-100 words; count 100)**

**Question:** What is the scope of VHA vaccination rollout and the impact of mRNA SARS-CoV-2 vaccination among Veterans?

**Findings:** Vaccination rollout reached all Veteran subpopulations in the first three months. Effectiveness of full vaccination with mRNA SARS-CoV-2 vaccines was 93.7% for preventing infection, comparable to that demonstrated in clinical trials. Effectiveness was similarly high for the elderly, ethnic and racial minorities, individuals with low income, homeless persons, and immunocompromised Veterans.

**Meaning:** Effective vaccines and their efficient and equitable distribution helped the VHA to reduce COVID-19 disease burden and disparities among Veterans within the first three months of vaccine distribution.

Abstract (limit: 350; count: 340)

Importance: The scope of vaccination rollout and effectiveness of mRNA SARS-CoV-2 vaccines in the United States (US), and US Veterans specifically, has not been fully assessed.

Objective: To estimate receipt of SARS-CoV-2 vaccines, and vaccine effectiveness (VE) against SARS-CoV-2 infection, subsequent disease-related severity and mortality.

Design, Setting, and Participants: First, receipt of any SARS-CoV-2 vaccine by March 7, 2021 was described for all enrolled and alive Veterans within the Veterans Health Administration (VHA). Second, to evaluate mRNA SARS-CoV-2 VE, a matched test negative case-control evaluation was conducted across all VHA facilities utilizing SARS-CoV-2 positive (cases [n=16,690]) and negative (controls [n=61,610]) tests from Veterans aged ≥18 years old who routinely sought care at a VHA facility and were tested for SARS-CoV-2 from December 14, 2020, through March 14, 2021.

Exposures: Vaccination histories were obtained from pharmacy and medical records to determine if patients were unvaccinated, partially vaccinated (from 7 days after first dose until day of second dose of mRNA SARS-CoV-2 vaccine), or fully vaccinated (from 7 days after second dose of mRNA SARS-CoV-2 vaccine) at time of SARS-CoV-2 test.

Main Outcome Measures: Primary outcomes were (1) vaccine receipt among Veterans and specific subpopulations, (2) VE calculated from odds ratios (ORs) with 95% confidence intervals (95% CI) for the association between SARS-CoV-2 infection and full vs. no vaccination, and (3) VE against infection for partial vs. no vaccination. VE against COVID-19-related hospitalization and death were also estimated.

Results: By March 7, 2020, among 6,170,750 Veterans, 1,547,045 (23.1%) received at least one SARS-CoV-2 vaccine. Based on the analysis of mRNA SARS-CoV-2 vaccines, VE against infection was 93.7% (95% CI 92.0-95.0) and 57.7% (95% CI 53.5-61.5) for full and partial vaccination (vs. no vaccination), respectively. VE was similar for subpopulations. VE against COVID-19-related hospitalization and death for full vs. no vaccination was 90.7% (95% CI 90.0-91.3) and 94.7% (95% CI 91.3-98.1), respectively.

Conclusion and Relevance: Vaccines are effective in reducing SARS-CoV-2 infections and disease-related severity and mortality in the Veteran population. Effective vaccine, as well as their efficient and equitable distribution, are important for reducing COVID-19 disease burden among Veterans.

## INTRODUCTION

On December 11, 2020, the United States (U.S.) Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Pfizer-BioNTech severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, BNT162b2, for the prevention of coronavirus disease 2019 (COVID-19) for individuals 16 years and older(1). One week later, the FDA issued an EUA for another mRNA-1273 vaccine, developed by Moderna, for individuals 18 years and older(2). Prior to these EUAs, the pandemic's impact on Veterans enrolled in the Veterans Health Administration (VHA), like elsewhere in the US, was devastating. Approximately 207,000 COVID-19 cases had been reported by the end of 2020 among VHA enrolled Veterans(3). Additionally, the burden of COVID-19 cases was distributed disproportionally among racial and ethnic minorities and could not be explained by underlying chronic conditions. About 35% infected were African American Veterans and 13% were Hispanic Veterans, although they comprised only 13% and 7% of the total VHA patient population, respectively. Over 10,000 of these patients died(3).

Once vaccines became available, VHA, working closely with the Centers for Disease Control and Prevention (CDC) and other federal partners, started an aggressive program to provide SARS-CoV-2 vaccines to Veterans as quickly and safely as possible. The success of the VHA vaccination program prompted the U.S. congress, on March 24$^{th}$, 2021, to pass the Strengthening and Amplifying Vaccination Efforts to Locally Immunize All Veterans and Every Spouse (SAVE LIVES) Act to authorize the Department of Veterans Affairs (VA) to expand vaccination efforts beyond enrolled Veterans (4). As real-world data are needed to constantly monitor the progress and the impact of the vaccination effort during this COVID-19 public health emergency, we present results on vaccine receipt and vaccine effectiveness (VE) from a test negative case control study of VHA enrolled Veterans for the three months following dissemination of COVID-19 vaccines.

The VHA is the largest integrated health care system in the U.S., providing both inpatient and outpatient clinical care to over nine million Veterans at more than 171 medical centers and 1,112 outpatient sites of care(5). Rapid deployment of the vaccination program was accompanied by VHA's nationwide SARS-CoV-2 testing effort, covering all VHA facilities, testing and recording both symptomatic and asymptomatic patients. Combined with accurate and timely recording of vaccination, this created an opportunity for a robust and well-powered test-negative case control analysis. Our objectives were to describe the extent of vaccine coverage and evaluate the effectiveness of mRNA vaccines in a diverse population that included socioeconomically disadvantaged and medically high-risk individuals. We focused this study on the first three months of the vaccination effort in the VHA. As a result, our analysis excluded data on the Johnson and Johnson SARS-CoV-2 vaccine.

## METHODS

The study protocol was approved by the institutional review board of the VA Medical Center in White River Junction, VT.

*Data Source*

We analyzed electronic medical record data from the VHA Corporate Data Warehouse (CDW). The CDW contains patient-level information on all outpatient and inpatient visits, treatments, dispensed prescriptions (both inpatient and outpatient, including vaccinations), and laboratory results rendered in VHA medical facilities. VHA also maintains its own mortality data.

*Study Design and Study Population*

First, vaccine receipt, defined as having at least one SARS-CoV-2 vaccine administered at a VHA facility between December 14, 2020 through March 7, 2021, was described for the population of VHA enrollees.

Second, we conducted a test-negative design (TND) case-control study to evaluate mRNA SARS-CoV-2 VE for preventing infection and a case-control study to evaluate VE against COVID-19-related hospitalization and death. The study population was restricted to veterans aged 18 years and older with residence in a U.S. state or Washington, D.C., who presented for SARS-CoV-2 PCR or antigen testing at a VHA outpatient or emergency room facility, or had testing within one day of hospitalization, during the study period. Patients were required to have enrolled in VHA at least two years prior to the study period and have had at least one inpatient or two outpatient visits in the past two years. Individuals meeting any of the following criteria were excluded: a SARS-CoV-2 diagnosis and/or a positive SARS-CoV-2 antigen or PCR test at any time between February 2020 and study initiation (December 14, 2020); hospitalization more than one day prior to testing; incomplete VHA medical records. Individuals administered a SARS-CoV-2 vaccine other than BNT162b2 or mRNA-1273, or both vaccines, or a third mRNA SARS-CoV-2 vaccine, were no longer eligible for study participation at the date of that vaccination.

For the TND case-control study to assess VE against infection, positive SARS-CoV-2 tests from qualifying patients were classified as cases. Negative SARS-CoV-2 tests from qualifying patients served as controls, and a maximum of four controls were matched with replacement to each case on Health and Human Services geographic region, and testing date within 14 days of case testing date as both these factors are related to both local disease burden and likelihood of testing positive for SARS-CoV-2, and vaccine exposure status. A qualifying patient could contribute both case and control data if the patient had a negative SARS-CoV-2 test more than 10 days prior to their positive test. In the population of patients with a positive SARS-CoV-2 test, a case-control study was conducted to assess VE in preventing COVID-19-related hospitalization and death. Up to four controls were matched without replacement to each case based on geographic region and testing date.

*Exposure, Outcome and Covariate Assessment*

Vaccination status was based on records of mRNA SARS-CoV-2 vaccination at a VHA facility captured in the CDW from December 14, 2020- February 28, 2021. A person was classified as unvaccinated until the day prior to the first vaccination, partially vaccinated from day 7 after the first vaccination until the day prior to the second vaccination, and fully vaccinated at 7 days after

the second vaccination (*Supplemental* Figure 1). Vaccination status was determined at the date of testing.

For the TND case-control study, medical records of RT-PCR or antigen tests for SARS-CoV-2 conducted at VHA facilities were used to identify cases (positive tests) and controls (negative tests). For the case-control study for analyzing hospitalization and death, a COVID-19-related hospitalization was identified by having an admission and discharge diagnosis of COVID-19 occurring any time after the first positive SARS-CoV-2 test. A death occurring in hospital with a COVID-19 discharge diagnosis or a death occurring within 14 days of a positive SARS-CoV-2 test was classified as a COVID-19-related death. Controls were drawn from patients with a positive SARS-CoV-2 who were not hospitalized for COVID-19 nor died during the study period.

Demographic and clinical characteristics of patients tested for SARS-Cov-2 were assessed at the time of testing or based on data from the prior two-year period, for characteristics such as comorbidities, Charlson Comorbidity Index and Care Assessment Needs (CAN) score (See *Supplemental* Table 1 for full definitions).

*Statistical Analyses*

For VHA enrollees and for subpopulations, vaccine coverage was reported as the frequency and proportion of individuals with at least one vaccination.

For the TND case-control study, for both unmatched and matched cases (positive SARS-CoV-2 test) and controls (negative SARS-CoV-2 test), baseline demographic and clinical characteristics of the tested patients were described by reporting frequency and proportion for categorical variables and median with interquartile range (IQR) for continuous variables. Missing data were reported. Standardized mean difference (SMD) was used to describe differences in characteristics between cases and controls. We used conditional logistic regression to calculate odds ratios (ORs) with 95% confidence interval (CI) for the association between positive SARS-CoV-2 testing and receipt of mRNA SARS-CoV-2 vaccine. VE was calculated as $(1- \mathrm{OR}_{\text{odds of SARS-CoV-2 in vaccinated vs odds of SARS-CoV-2 in unvaccinated}})$ x 100%. Analyses were conducted comparing partial vaccination, days 14-20 after first dose, first 7 days after second dose, and full vaccination versus no vaccination. Models for adjusted analyses included covariates for potential confounders of the association between vaccination status and testing positive for SARS-Cov2. Conditional logistic regression for the case control analyses of hospitalization and death were conducted similarly. All analyses were conducted in SAS, version 7.

## Results

*Vaccination Coverage*

By March 7, 2021, 1,547,045 (23.1%) VHA enrollees were administered at least one dose of a SARS-CoV-2 vaccine at a VHA facility (Table 1). Vaccine receipt was higher (33.8%) among veterans ≥65 years old. Vaccination receipt was 20.6%, 24.9%, and 23.9% for Hispanic, black

and white Veterans, respectively. Veterans living in urban areas had vaccine receipt than those in rural areas (24.6% vs. 16.4% for urban vs. highly rural, based on Rural-Urban Community Area (RUCA) codes(6)). VHA's vaccination effort reached Veterans in every state, of all ages, races, and ethnicities. It reached homeless Veterans (19.3%), and those living in nursing homes (40.9%). It has also reached Veterans with significant comorbid conditions such as diabetes (39.8%), hypertension (38.8%), cancer (47.9%), renal disease (46.1%), and immunocompromising diseases (45.2%).

*Study Population*

We identified 15,404 positive SARS-CoV-2 tests that were classified as cases and 497,584 negative tests that were classified as controls (Figure 1). After matching, there were 15,404 cases and 61,610 controls. Baseline characteristics for the cases and controls before and after matching are shown in Table 2. At time of testing, 14,799 (96.1%) cases and 50,831 (82.5%) controls were unvaccinated in the matched analysis. Compared with controls, cases were younger and more likely to be white. Cases and controls were similar in terms of region and time of testing after being matched on these (Table 2).

*Vaccine Effectiveness*

Table 3 shows the estimated VE for full and partial vaccination for a documented positive SARS-CoV-2 test. In the adjusted analysis, the VE for the overall population for full and partial vaccination was 93.7% (95% CI 92.0-95.0) and 57.7% (95% CI 53.5-61.5), respectively. VE was similar to that in the overall population for most subpopulations. VE for full vaccination was a few percentage points lower among patients who were overweight/obese (87.3% (95% CI 82.0-91.0)), immunocompromised (87.5% (95%CI 81.6-91.5)), and those with comorbidities such as cancer and congestive heart failure. VE did not differ by age, sex, or urban/rural status. The VE for Hispanic patients was lower than the VE for black and white patients, with only a small overlap in 95% CIs. For subpopulations, the point estimates for partial vaccination at 14-20 days after the first dose were higher than those for partial vaccination measured starting 7 days after the first dose.

Results from the indirect analysis of VE against COVID-19-related hospitalization and death are displayed in Table 4. Against hospitalization for the overall population, in the matched analysis, the VE for full and partial vaccination was 90.7% (95% CI 90.0-91.3) and 77.8% (95% CI 74.3-77.2), respectively. Against death for the overall population, in the matched analysis, the VE for full and partial vaccination was 94.7% (95% CI 91.3-98.1) and 84.4% (95% CI 80.1-88.8), respectively.

## Discussion

The VHA's vaccination effort has successfully reached all demographic groups among Veterans in the first three months. Notably, vaccine receipt was at least as high among black compared to white veterans. This nationwide study on mRNA SARS-CoV-2 vaccines in the U.S. demonstrated VE against infection was 93.7%, comparable to that reported in the clinical trials

for these vaccines(7, 8). Importantly, VE was similarly high in subpopulations, and the vaccines indicate effectiveness against COVID-19-related hospitalization and death.

Our estimates on VE are comparable to those reported in previous observational studies. The VE for full vaccination against infection reported here (93.7% [95% CI 92.0-95.0%]) is similar to that reported in a study based on national surveillance data in Israel following the rollout of BNT162b2 among individuals ≥16 years old (95.3% [95% CI 94.9-95.7%])(10), a study conducted among individuals ≥16 years old in Israel's largest healthcare organization (92% [95% CI 88-95%])(11), a prospective study among vaccinated healthcare workers in the United Kingdom (85% [95% CI 74-96%])(12), and a study among essential and frontline workers in the U.S. (90% [95% CI 68-97%])(13). The VE for full vaccination against COVID-19-related hospitalization (90.7%) and death (94.7%) indicate that full vaccination affords strong protection against these outcomes, however, the lack of sufficient sample size limited the ability to study these outcomes among subpopulations. VE against COVID-19-related hospitalization was estimated to be 97.2% (95% CI 96.8-97.5%) in one study in Israel(10) and 87% (95% CI 55-100%) in another study in Israel(11) and 94% (95% CI 49-99%) in a U.S. study of patients ≥65 years old(14). VE against COVID-19-related death was estimated to be 96.7% (95%CI 96.0-97.3%) in a study in Israel(10). The current study focused on the U.S. population adds important context to our understanding on VE because vaccination rollout and SARS-CoV-2 variants have differed globally, and the prior study in the U.S. focused on the working population with high risk of SARS-CoV-2 exposure(14). In Israel and the United Kingdom, mRNA SARS-CoV-2 vaccine distribution included only BNT162b2, and the United Kingdom extended the dose interval between vaccinations to vaccinate their population more rapidly, limiting the ability to assess full vaccination in a real-world setting(11, 15). Furthermore, each country has distinct demographic characteristics, and the current study allowed for a more in-depth analysis of VE in subpopulations for whom the COVID-19 disease burden has been greater, such as black and Hispanic patients.

Many important prior studies had limited sample size, be it clinical trials or observational studies (8, 10, 12, 13, 16), so the question regarding VE of SARS-CoV-2 vaccines for people with underlying medical conditions remained largely unanswered even though some conditions may predispose individuals to have severe consequences from infection(17). Dagan et al(11) reported that VE may be slightly lower among persons with a higher number of comorbidities. Vaccine immunogenicity for people who are immunocompromised has not been explored. We found that, when fully vaccinated, the VE is 87.5% (95% CI, 81.6-91.5) for immunocompromised patients, which is attenuated but reassuring. For those partially vaccinated, the VE is much lower at 43.1% (95% CI, 32.0-52.5). Further exploration of these patients by underlying disease and treatment is warranted given the response to infection may vary accordingly(17).

As our study and others have shown (7, 12, 13, 15, 16), VE against SARS-CoV-2 infection is high even after just the first dose. In the analysis of vaccination 14-20 days after the first dose, we observed that VE was higher than partial vaccination measured at 7 days after the first dose, suggesting that patients with comorbidities may benefit from longer protective measures despite being partially vaccinated.

As COVID-19 has disproportionally affected racial and ethnic minorities and low-income communities(18-20), VHA was able to vaccinate minority and low-income Veterans with rates similar to the overall population. VE for black Veterans was similar to that observed in white Veterans, after adjusting for potential confounders such as underlying medical conditions. However, the VE for Hispanic Veterans was lower, warranting further exploration. The rates of SARS-CoV-2 testing were significantly higher among racial and ethnic minorities in the first half of 2020. Prior to vaccination, black and Hispanic Veterans were at 30% to 40% higher risk of infection than their white counterparts(19). After well-maintained effort to provide vaccination to all Veterans, regardless of color and income, we found that the risk of infection following full vaccination was reduced for all (VE was 93.3%, 73.5% and 90.4% for black, Hispanic, and white patients, respectively). In other words, protection with vaccination is similar among vaccinated Veterans regardless of race and ethnicity, suggesting equitable distribution of vaccines could be an effective means to reduce racial and socioeconomic disparity in COVID-19 disease burden.

Limitations

A main concern regarding test-negative studies is misclassification. Our study relied on records of vaccination collected prospectively and in near real-time rather than subjects' memory. While this study demonstrated vaccine-coverage reached all demographic subgroups, the vaccine coverage reported here may be a conservative estimate(9). Moreover, by the end of 2020, VHA had standardized its testing and case definitions, unlike the beginning of the pandemic(21). In addition to SARS-CoV-2–positive test results, we coupled them with a clinical syndrome in a sensitivity analysis to reduce potential misclassification and found the VE was similar to the main analysis at 91% (95%CI 87, 93) (*Supplemental* Table 2). Some Veterans could have received vaccination through the VHA but were hospitalized in a non-VA facility, especially in rural communities (22). We limited the study population to those who routinely sought care at VHA facilities to minimize the likelihood of including patients who were vaccinated or sought treatment for COVID-19 elsewhere. To further address this, we utilized Medicare data that were available for Veterans enrolled in Medicare who had a positive SARS-CoV-2 test and repeated the analysis including any records of vaccination and hospitalization outside the VA for these patients. The results again were similar with a VE of 87% (95%CI 83, 89) (*Supplemental* Table 3). Nevertheless, there could still be residual misclassification which has the potential to bias the results towards the null.

## Conclusion

Over a period of only three months after the first SARS-CoV-2 vaccine was authorized, the VHA successfully tested and vaccinated millions of Veterans against SARS-CoV-2. We found mRNA vaccines to be highly effective against the risk of SARS-CoV-2 infection. In the effort to contain this unprecedented pandemic, the effectiveness of the vaccines combined with the efficiency of their deployment within the VHA resulted in attenuated COVID-19 disease burden among all VHA enrolled Veterans and in reducing the disproportioned disease burden among vulnerable populations.

**Acknowledgements**

We acknowledge Dr. Hector S. Izurieta and Dr. Jeffrey Roberts (FDA Office of Vaccines Research and Center for Biologics Evaluation and Research) for their contributions to the study conception and design, analysis, writing, and review of this manuscript for content accuracy.

References

1. FDA. FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine [Available from: https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19.
2. FDA. FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine [Available from: https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid.
3. Affairs DoV. Department of Veterans Affairs COVID-19 National Summary [Available from: https://www.accesstocare.va.gov/Healthcare/COVID19NationalSummary.
4. Affairs TUSSCoV. BREAKING: Bipartisan Bill Expanding Vaccine Access for Vets & Families Signed Into Law [Available from: https://www.veterans.senate.gov/newsroom/majority-news/breaking-bipartisan-bill-expanding-vaccine-access-for-vets-and-families-signed-into-law.
5. Administration VH. [Available from: https://www.va.gov/health/aboutvha.asp.
6. Affairs UDoV. Office of Rural Health [Available from: https://www.ruralhealth.va.gov/rural-definition.asp.
7. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N Engl J Med. 2020;383(27):2603-15.
8. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-16.
9. CDC. COVID Data Tracker [Available from: https://covid.cdc.gov/covid-data-tracker/#vaccination-demographics-trends]. .
10. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819-29.
11. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021;384(15):1412-23.
12. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021;397(10286):1725-35.
13. Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(13):495-500.
14. Tenforde MW, Olson SM, Self WH, Talbot HK, Lindsell CJ, Steingrub JS, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged >/=65 Years - United States, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(18):674-9.
15. Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. Bmj. 2021;373:n1088.
16. Angel Y, Spitzer A, Henig O, Saiag E, Sprecher E, Padova H, et al. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers. JAMA. 2021.
17. Fung M, Babik JM. COVID-19 in Immunocompromised Hosts: What We Know So Far. Clin Infect Dis. 2021;72(2):340-50.

18. Vahidy FS, Nicolas JC, Meeks JR, Khan O, Pan A, Jones SL, et al. Racial and ethnic disparities in SARS-CoV-2 pandemic: analysis of a COVID-19 observational registry for a diverse US metropolitan population. BMJ Open. 2020;10(8):e039849.
19. Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King JT, Jr., Skanderson M, et al. Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study. PLoS Med. 2020;17(9):e1003379.
20. Abedi V, Olulana O, Avula V, Chaudhary D, Khan A, Shahjouei S, et al. Racial, Economic and Health Inequality and COVID-19 Infection in the United States. medRxiv. 2020.
21. Patel MM, Jackson ML, Ferdinands J. Postlicensure Evaluation of COVID-19 Vaccines. JAMA. 2020;324(19):1939-40.
22. McDermott D, Hudman, J., Cox, C. The Veteran Health Administration's Role During the COVID-19 Response [Available from: https://www.healthsystemtracker.org/brief/the-veteran-health-administrations-role-during-the-covid-19-response/.

## Tables & Figures






**Figure 1**. SARS-CoV-2 PCR and antigen tests (December 14, 2020-March 7, 2021) meeting study criteria

**Table 1**. COVID-19 Vaccination Coverage through March 7, 2021 among VHA Enrollees[a]

| | Number of enrollees [A] | Vaccinated enrollees [B] | % Vaccination coverage [B/A] |
|---|---|---|---|
| All enrollees | 6,710,750 | 1,547,045 | 23.1% |
| Age range, y | | | |
| 18-44 | 1,382,988 | 63,794 | 4.6% |
| 45-64 | 1,950,293 | 340,959 | 17.5% |
| 65-74 | 1,895,735 | 625,177 | 33.0% |
| 75-84 | 1,000,503 | 367,395 | 36.7% |
| ≥85 | 481,231 | 149,720 | 31.1% |
| ≥65 | 3,377,469 | 1,142,292 | 33.8% |
| Sex | | | |
| Female | 634,302 | 95,579 | 15.1% |
| Male | 6,076,448 | 1,451,466 | 23.9% |
| Race or ethnic group | | | |
| Black | 1,110,223 | 276,750 | 24.9% |
| Hispanic | 464,284 | 95,845 | 20.6% |
| White | 4,407,279 | 1,051,749 | 23.9% |
| Other | 384,981 | 80,993 | 21.0% |
| Missing | 343,983 | 41,708 | 12.1% |
| Urban-rural classification | | | |
| Highly rural | 83,386 | 13,649 | 16.4% |
| Rural | 2,176,409 | 437,793 | 20.1% |
| Urban | 4,450,955 | 1,095,603 | 24.6% |
| VHA defined priority group | | | |
| 1-4 | 2,545,311 | 552,638 | 21.7% |
| 5-6 | 2,156,949 | 475,988 | 22.1% |
| 7-8 | 2,008,490 | 518,419 | 25.8% |
| Nursing home resident | 32,063 | 13,103 | 40.9% |
| Homeless | 124,850 | 24,103 | 19.3% |
| Low Income | 663,649 | 138,463 | 20.9% |
| Comorbidities | | | |
| Asthma | 336,849 | 135,672 | 40.3% |
| Cancer | 191,185 | 91,660 | 47.9% |
| Coronary artery disease | 367,556 | 161,922 | 44.1% |
| CAMET | 20,768 | 10,520 | 50.7% |
| Congestive heart failure | 166,994 | 76,177 | 45.6% |
| Chronic heart disease | 212,324 | 97,836 | 46.1% |
| Chronic obstructive pulmonary disease | 363,203 | 146,639 | 40.4% |
| Cardiovascular disease | 114,495 | 48,279 | 42.2% |
| Dementia | 72,101 | 26,014 | 36.1% |
| Dyslipidemia | 745,217 | 289,270 | 38.8% |
| HIV | 19,422 | 7,758 | 39.9% |

| | | | |
|---|---|---|---|
| Hypertension | 1,473,558 | 572,278 | 38.8% |
| Liver disease, mild | 94,328 | 36,314 | 38.5% |
| Liver disease, severe | 8,066 | 3,336 | 41.4% |
| Myocardial infarction | 36,544 | 16,591 | 45.4% |
| PLEG | 19,979 | 9,048 | 45.3% |
| Peptic ulcer disease | 8,683 | 3,761 | 43.3% |
| Peripheral vascular disease | 140,128 | 65,357 | 46.6% |
| Rheumatoid arthritis | 43,543 | 17,674 | 40.6% |
| Renal disease | 219,051 | 100,879 | 46.1% |
| Immunocompromised | 455,601 | 206,098 | 45.2% |
| Diabetes mellitus | 967,034 | 384,596 | 39.8% |

Abbreviations: VHA, Veterans Health Association; HIV, human immunodeficiency virus.
[a]Definitions for urban-rural classification, VHA defined priority group, and comorbidities are provided in Supplemental Table 1.

**Table 2**. Exposure Status and Baseline Characteristics of Study Participants[a]

| | Unmatched | | | Matched | | |
|---|---|---|---|---|---|---|
| | Cases (n=15,404) | Controls (n=497,584) | SMD[b] | Cases (n=15,404) | Controls (n=61,610) | SMD[b] |
| Vaccination status, No. (%) | | | | | | |
| Full | 72 (1) | 34,979 (7) | 35 | 72 (1) | 4,959 (8) | 38 |
| Partial | 533 (4) | 36,545 (7) | 17 | 533 (4) | 5,820 (9) | 25 |
| None | 14,799 (96) | 426,060 (86) | 37 | 14,799 (96) | 50,831 (83) | 45 |
| Vaccine manufacturer, No. (%) | | | | | | |
| Moderna | 342 (2) | 39,007 (8) | 26 | 342 (2) | 6,182 (10) | 33 |
| Pfizer | 263 (2) | 32,517 (7) | 24 | 263 (2) | 4,597 (8) | 28 |
| Missing | 14,799 (96) | 426,060 (86) | 37 | 14,799 (96) | 50,831 (83) | 45 |
| Month of Test, No. (%) | | | | | | |
| 2020-Dec. | 4,603 (30) | 111,052 (22) | 17 | 4,603 (30) | 18,349 (30) | 0 |
| 2021-Jan. | 7,306 (47) | 190,353 (38) | 18 | 7,306 (47) | 25,504 (41) | 12 |
| 2021-Feb. | 2,962 (19) | 155,601 (31) | 28 | 2,962 (19) | 14,537 (24) | 11 |
| 2021-Mar. | 533 (4) | 40,578 (8) | 20 | 533 (4) | 3,220 (5) | 9 |
| Care setting for test, No. (%) | | | | | | |
| ED/At Admission | 6,959 (45) | 119,201 (24) | 46 | 6,959 (45) | 15,982 (26) | 41 |
| Outpatient | 8,445 (55) | 378,383 (76) | 46 | 8,445 (55) | 45,629 (74) | 41 |
| Age, y | | | | | | |
| 18-44 | 2,535 (17) | 73,236 (15) | 5 | 2,535 (17) | 668 (1) | 56 |
| 45-64 | 5,409 (35) | 177,629 (36) | 1 | 5,409 (35) | 22,642 (37) | 3 |
| 65-74 | 4,757 (31) | 160,157 (32) | 3 | 4,757 (31) | 24,673 (40) | 19 |
| 75-84 | 1,928 (13) | 64,096 (13) | 1 | 1,928 (13) | 9,481 (15) | 8 |
| 85+ | 775 (5) | 22,466 (5) | 2 | 775 (5) | 4,147 (7) | 7 |
| Sex, No. (%) | | | | | | |
| Female | 1,457 (10) | 55,591 (11) | 6 | 1,457 (10) | 5,868 (10) | 0 |
| Male | 13,947 (91) | 441,993 (89) | 6 | 13,947 (91) | 55,742 (91) | 0 |
| Race, No. (%) | | | | | | |
| Black | 3,848 (25) | 121,718 (25) | 1 | 3,848 (25) | 19,807 (32) | 16 |
| Hispanic | 1,014 (7) | 34,816 (7) | 2 | 1,014 (7) | 2,884 (5) | 8 |
| White | 9,620 (63) | 303,234 (61) | 3 | 9,620 (63) | 34,731 (56) | 12 |
| Other | 922 (6) | 37,816 (8) | 6 | 922 (6) | 4,188 (7) | 3 |
| Rurality, No. (%) | | | | | | |
| Highly rural | 107 (1) | 3,015 (1) | 1 | 107 (1) | 376 (1) | 1 |
| Rural | 4,667 (30) | 120,555 (24) | 14 | 4,667 (30) | 14,758 (24) | 14 |
| Urban | 10,630 (69) | 374,014 (75) | 14 | 10,630 (69) | 46,476 (75) | 14 |
| HHS region, No. (%) | | | | | | |
| Region 1 | 803 (5) | 23,289 (5) | 2 | 803 (5) | 3,212 (5) | 0 |
| Region 2 | 763 (5) | 23,723 (5) | 1 | 763 (5) | 3,052 (5) | 0 |
| Region 3 | 2,286 (15) | 48,958 (10) | 15 | 2,286 (15) | 9,143 (15) | 0 |
| Region 4 | 3,944 (26) | 138,087 (28) | 4 | 3,944 (26) | 15,976 (26) | 0 |
| Region 5 | 1,661 (11) | 67,333 (14) | 8 | 1,661 (11) | 6,644 (11) | 0 |
| Region 6 | 3,425 (22) | 58,556 (12) | 28 | 3,425 (22) | 13,696 (22) | 0 |
| Region 7 | 714 (5) | 23,441 (5) | 0 | 714 (5) | 2,856 (5) | 0 |
| Region 8 | 445 (3) | 15,880 (3) | 2 | 445 (3) | 1,780 (3) | 0 |
| Region 9 | 976 (6) | 80,345 (16) | 31 | 976 (6) | 3,904 (6) | 0 |
| Region 10 | 337 (2) | 17,946 (4) | 8 | 337 (2) | 1,348 (2) | 0 |
| Homeless, No. (%) | 620 (4) | 32,933 (7) | 12 | 620 (4) | 4,646 (8) | 15 |

| | | | | | | |
|---|---|---|---|---|---|---|
| Low income, No. (%) | 2,139 (14) | 77,418 (16) | 5 | 2,139 (14) | 12,059 (20) | 15 |
| Nursing home use, No. (%) | 124 (1) | 9,212 (2) | 9 | 124 (1) | 2,021 (3) | 18 |
| VA priority group, No. (%) | | | | | | |
| 1-4 | 5,823 (38) | 210,310 (42) | 9 | 5,823 (38) | 32,276 (52) | 29 |
| 5-6 | 5,131 (33) | 161,290 (32) | 2 | 5,131 (33) | 17,182 (28) | 12 |
| 7-8 | 4,450 (29) | 125,984 (25) | 8 | 4,450 (29) | 12,152 (20) | 22 |
| Quan's CCI | | | | | | |
| Median (IQR) | 0 (0, 2) | 1 (0, 2) | | 0 (0, 2) | 1 (0, 3) | |
| BMI, No. (%) | | | | | | |
| Missing | 5,725 (37) | 181,496 (37) | 1 | 5,725 (37) | 22,567 (37) | 1 |
| Normal | 2,025 (13) | 89,133 (18) | 13 | 2,025 (13) | 12,110 (20) | 18 |
| Overweight/ obese | 7,654 (50) | 226,955 (46) | 8 | 7,654 (50) | 26,933 (44) | 12 |
| Comorbidities | | | | | | |
| Asthma | 1,726 (11) | 68,761 (14) | 8 | 1,726 (11) | 11,803 (19) | 22 |
| Cancer | 992 (6) | 40,710 (8) | 7 | 992 (6) | 5,923 (10) | 12 |
| Cancer (metastatic) | 148 (1) | 7,718 (2) | 5 | 148 (1) | 1,181 (2) | 8 |
| Coronary artery disease | 2,018 (13) | 68,512 (14) | 2 | 2,018 (13) | 11,050 (18) | 13 |
| Congestive heart failure | 1,208 (8) | 45,941 (9) | 5 | 1,208 (8) | 7,857 (13) | 16 |
| Chronic kidney disease | 1,458 (10) | 50,718 (10) | 2 | 1,458 (10) | 8,585 (14) | 14 |
| Chronic obstructive pulmonary disease | 1,866 (12) | 74,799 (15) | 9 | 1,866 (12) | 12,812 (21) | 24 |
| Cardiovascular disease | 676 (4) | 30,431 (6) | 8 | 676 (4) | 5,464 (9) | 18 |
| Dementia | 489 (3) | 30,981 (6) | 14 | 489 (3) | 6,619 (11) | 30 |
| Diabetes mellitus (complicated) | 1,827 (12) | 58,907 (12) | 0 | 1,827 (12) | 10,107 (16) | 13 |
| Diabetes mellitus (uncomplicated) | 2,830 (18) | 77,950 (16) | 7 | 2,830 (18) | 11,647 (19) | 1 |
| Dyslipidemia | 3,574 (23) | 122,001 (25) | 3 | 3,574 (23) | 18,732 (30) | 16 |
| HIV | 82 (1) | 4,069 (1) | 3 | 82 (1) | 923 (2) | 10 |
| Hypertension | 6,694 (44) | 217,124 (44) | 0 | 6,694 (44) | 33,962 (55) | 23 |
| Liver disease (mild) | 578 (4) | 24,199 (5) | 5 | 578 (4) | 4,098 (7) | 13 |
| Liver disease (moderate/severe) | 78 (1) | 3,781 (1) | 3 | 78 (1) | 584 (1) | 5 |
| Myocardial infarction (history) | 334 (2) | 13,182 (3) | 3 | 334 (2) | 2,122 (3) | 8 |
| Para/hemiplegia | 101 (1) | 10,477 (2) | 12 | 101 (1) | 1,877 (3) | 18 |
| Peptic ulcer disease | 79 (1) | 3,590 (1) | 3 | 79 (1) | 490 (1) | 4 |
| Peripheral vascular disease | 889 (6) | 37,031 (7) | 7 | 889 (6) | 6,342 (10) | 17 |
| Rheumatoid arthritis | 218 (1) | 7,181 (1) | 0 | 218 (1) | 1,117 (2) | 3 |
| Renal disease | 1,491 (10) | 51,562 (10) | 2 | 1,491 (10) | 8,706 (14) | 14 |
| Atrial fibrillation | 1,205 (8) | 42,972 (9) | 3 | 1,205 (8) | 6,621 (11) | 10 |
| Anaphylaxis (history) | - (0) | 87 (0) | 2 | - (0) | 19 (0) | 2 |
| Arthritis | 1,368 (9) | 48,622 (10) | 3 | 1,368 (9) | 8,294 (14) | 15 |
| Bleeding diathesis | - (0) | 14 (0) | 1 | - (0) | - (0) | |
| Brocheostasis | 19 (0) | 947 (0) | 2 | 19 (0) | 154 (0) | 3 |

| | | | | | | |
|---|---|---|---|---|---|---|
| Depression | 2,254 (15) | 86,456 (17) | 7 | 2,254 (15) | 12,162 (20) | 14 |
| Down Syndrome | - (0) | - (0) | | - (0) | - (0) | |
| Embolism (history) | 304 (2) | 12,795 (3) | 4 | 304 (2) | 2,164 (4) | 9 |
| Falls (history) | 114 (1) | 6,726 (1) | 6 | 114 (1) | 1,163 (2) | 10 |
| Gout | 53 (0) | 1,915 (0) | 1 | 53 (0) | 284 (1) | 2 |
| Hepatitis B | 28 (0) | 702 (0) | 1 | 28 (0) | 158 (0) | 2 |
| Hepatitis C | 88 (1) | 3,995 (1) | 3 | 88 (1) | 880 (1) | 9 |
| Hyperlipidemia | 4,628 (30) | 151,284 (30) | 1 | 4,628 (30) | 23,000 (37) | 15 |
| Interstitial lung Disease | 118 (1) | 5,790 (1) | 4 | 118 (1) | 965 (2) | 7 |
| Impaired mobility | 39 (0) | 4,903 (1) | 9 | 39 (0) | 1,026 (2) | 15 |
| Musculoskeletal disorder | 7,390 (48) | 255,372 (51) | 7 | 7,390 (48) | 36,063 (59) | 21 |
| Mycoses | 777 (5) | 37,023 (7) | 10 | 777 (5) | 6,979 (11) | 23 |
| Obesity | 1,710 (11) | 54,124 (11) | 1 | 1,710 (11) | 7,355 (12) | 3 |
| Paranoia | 214 (1) | 11,408 (2) | 7 | 214 (1) | 2,016 (3) | 13 |
| Parkinsons | 117 (1) | 7,521 (1) | 7 | 117 (1) | 1,244 (2) | 11 |
| Drug-induced anaphylaxis | 190 (1) | 6,912 (1) | 1 | 190 (1) | 1,169 (2) | 5 |
| Sickle cell disease | 11 (0) | 387 (0) | 0 | 11 (0) | 87 (0) | 2 |
| Solid organ transplant recipient | 69 (0) | 2,756 (1) | 2 | 69 (0) | 422 (1) | 3 |
| Stroke / transient ischemic attack | 339 (2) | 16,671 (3) | 7 | 339 (2) | 3,041 (5) | 15 |
| Urinary tract infection | 371 (2) | 19,079 (4) | 8 | 371 (2) | 3,594 (6) | 17 |
| Immunocompromised | 2,324 (15) | 96,783 (20) | 12 | 2,324 (15) | 14,719 (24) | 22 |
| CAN Score, Mean (SD) | | | | | | |
| Mortality-1 year | 5.2% (10) | 5.7% (11) | 5 | 5.2% (10) | 7.6% (12%) | 22 |
| Mortality-90 days | 1.5% (4) | 1.7% (4) | 4 | 1.5% (4) | 2.3% (5%) | 17 |
| Event-1 year | 20.5% (20) | 20.6% (21) | 1 | 20.5% (20) | 24.1% (23%) | 16 |
| Event-90 days | 8.0% (11) | 8.3% (12) | 3 | 8.0% (11) | 10.1% (14%) | 17 |
| Hospitalization-1 year | 17.8% (18) | 18.6% (19) | 4 | 17.8% (18) | 21.6% (21%) | 19 |
| Hospitalization-90 days | 7.2% (10) | 7.8% (11) | 6 | 7.2% (10) | 9.5% (13%) | 20 |
| Any COVID-19 symptoms | 10,499 (68) | 105,464 (21) | 107 | 10,499 (68) | 13,067 (21) | 107 |
| Influenza vaccination (2019/20 season) | 135 (1) | 4,521 (1) | 0 | 135 (1) | 753 (1) | 3 |
| Influenza vaccination (2020/21 season) | 1,570 (10) | 54,432 (11) | 2 | 1,570 (10) | 8,506 (14) | 11 |

Abbreviations: BMI, body mass index; CAN Score, Care Assessment Needs score; No., number; SMD, standardized mean difference; VA, Veterans Affairs.
[a]Definitions for variables are provided in Supplemental Table 1.
[b]SMD of 10 or greater was used to identify imbalance between cases and controls.

**Table 3**. Vaccine Effectiveness Against Laboratory Confirmed SARS-CoV-2 Infection[a]

| | VE, % (95%CI) | | | |
|---|---|---|---|---|
| | Full vs. no vaccination | | Partial vs. no vaccination | |
| | Unadjusted | Adjusted[b] | Unadjusted | Adjusted[b] |
| Overall | 96 (95, 97) | 94 (92, 95) | 70 (67%, 73%) | 58 (54, 61) |
| Age, y | | | | |
| 18-64 | 91 (84, 95) | 91 (83, 95) | 59 (49, 67) | 52 (40, 62) |
| ≥65 | 92 (90, 94) | 92 (89, 94) | 57 (52, 61) | 54 (48, 58) |
| 18-79 | 91 (88, 93) | 91 (88, 93) | 55 (50, 59) | 53 (48, 58) |
| ≥80 | 93 (89, 96) | 93 (88, 96) | 59 (50, 66) | 56 (46, 64) |
| VHA defined priority group | | | | |
| 1-4 | 93 (90, 95) | 93 (89, 95) | 60 (53, 65) | 56 (49, 63) |
| 5-6 | 88 (83, 92) | 90 (85, 93) | 53 (45, 60) | 55 (46, 62) |
| 7-8 | 90 (84, 94) | 90 (84, 94) | 43 (33, 52) | 47 (37, 56) |
| Race or ethnic group | | | | |
| Black | 94 (89, 97) | 93 (88, 96) | 49 (39, 58) | 48 (37, 57) |
| Hispanic | 82 (59, 92) | 73 (38, 89) | 52 (25, 69) | 44 (13, 65) |
| White | 91 (88, 93) | 90 (87, 93) | 56 (51, 61) | 55 (50, 60) |
| Other | 98 (85, 100) | 98 (86, 100) | 61 (40, 75) | 65 (46, 78) |
| Sex | | | | |
| Female | 86 (62, 95) | 82 (51, 94) | 73 (50, 85) | 65 (35, 81) |
| Male | 92 (90, 94) | 92 (90, 94) | 54 (49, 58) | 54 (50, 58) |
| Urban-rural | | | | |
| Rural | 93 (89, 96) | 93 (89, 96) | 60 (52, 66) | 58 (50, 65) |
| Urban | 91 (88, 93) | 90 (87, 93) | 52 (47, 57) | 50 (44, 55) |
| BMI | | | | |
| Normal | 88 (79, 93) | 91 (84, 95) | 43 (29, 55) | 51 (38, 61) |
| Obese | 88 (83, 92) | 87 (82, 91) | 48 (41, 55) | 45 (37, 52) |
| Missing | 95 (92, 97) | 94 (91, 96) | 63 (57, 68) | 60 (54, 66) |
| Underlying medical conditions | | | | |
| Cancer | 85 (74, 91) | 84 (73, 91) | 45 (27, 58) | 43 (25, 56) |
| Congestive heart failure | 87 (80, 91) | 85 (76, 90) | 57 (46, 66) | 54 (42, 64) |
| Chronic kidney disease | 93 (87, 96) | 91 (85, 94) | 54 (43, 63) | 55 (45, 64) |
| Diabetes mellitus | 93 (90, 95) | 92 (88, 94) | 59 (53, 65) | 56 (49, 62) |
| Hypertension | 91 (88, 93) | 91 (88, 93) | 56 (50, 61) | 56 (51, 61) |
| Immunocompromised | 86 (79, 90) | 88 (82, 92) | 42 (31, 52) | 43 (32, 52) |
| Adjusted VE, % (95%CI) [reference group: unvaccinated] | | | | |
| | 14 to 20 days after dose 1 | Partial vaccination | Full vaccination | |
| BMI | | | | |
| Normal | 57 (37, 70) | 51 (38, 61) | (84, 95) | |
| Obese | 58 (46, 67) | 45 (37, 52) | 87 (82, 91) | |
| Missing | 68 (58, 76) | 60 (54, 66) | 94 (91, 96) | |
| Underlying medical conditions | | | | |
| Cancer | 56 (29, 73) | 43 (25, 56) | 84 (73, 91) | |
| Congestive heart failure | 70 (53, 81) | 54 (42, 64) | 85 (76, 90) | |
| Chronic kidney disease | 66 (49, 78) | 55 (45, 64) | 91 (85, 94) | |
| Diabetes mellitus | 64 (53, 72) | 56 (49, 62) | 92 (88, 94) | |
| Hypertension | 62 (53, 69) | 56 (51, 61) | 91 (88, 93) | |
| Immunocompromised | 57 (41, 68) | 43 (32, 52) | 88 (82, 92) | |

Abbreviations: BMI, body mass index; VE, vaccine effectiveness; VHA, Veterans Health Affairs.
[a]See Supplemental Table 1 for definitions of variables in this table.
[b]The adjusted variables include the following: age, BMI, cancer, congestive heart failure, chronic kidney disease, diabetes mellitus, hypertension, immunocompromised, VA priority level, race, sex, rurality.

**Table 4**. Vaccine Effectiveness Against COVID-19-related Hospitalization and Death[a]

| | VE against COVID-19-related hospitalization, % (95%CI) | | | |
|---|---|---|---|---|
| | Full vs. no vaccination | | Partial vs. no vaccination | |
| | | Adjusted[b] | | Adjusted[b] |
| Overall | 86.9 (86.4,87.3) | 90.7 (90.0,91.3) | 72.7 (71.5,73.8) | 77.8 (74.3,77.2) |
| | VE against COVID-19-related death, % (95%CI) | | | |
| | Full vs. no vaccination | | Partial vs. no vaccination | |
| | Unadjusted | Adjusted[b] | | Adjusted[b] |
| Overall | 96.4 (94.2,98.6) | 94.7 (91.3,98.1) | 87.5 (81.6,93.4) | 84.4 (80.1,88.8) |

Abbreviations: BMI, body mass index; VE, vaccine effectiveness; VHA, Veterans Health Affairs.
[a]See Supplemental Table 1 for definitions of variables in this table.
[b]The adjusted variables include the following: age, BMI, cancer, congestive heart failure, chronic kidney disease, diabetes mellitus, hypertension, immunocompromised, VA priority level, race, sex, rurality.




**Supplemental Figure 1**. Vaccination exposure classification

**Supplemental Table 1**. Definitions of variables

| Variable | Values | Definition | Timing |
|---|---|---|---|
| Age | Integer | Age as of the specimen collection date for SARS-CoV-2 lab test | Table 1: Determined at March 7, 2021; Table 2: Determined at the specimen collection date for SARS-CoV-2 lab test during the study period (December 14, 2020 to March 7, 2021) |
| Sex | Female/male | As defined in VHA data | Most recent available |
| Race | Black<br>Hispanic<br>White<br>Other | Black: non-Hispanic black<br>Hispanic: Hispanic any race<br>White: non-Hispanic white<br>Other: non-Hispanic other race, missing race, declined to state, unknown | Most recent available |
| Rurality | Highly Rural<br>Rural<br>Urban | VHA defined based on the Rural-Urban Community Area (RUCA) system [ https://www.ruralhealth.va.gov/rural-definition.asp] | Most recent available |
| VHA defined priority group | 1, 2, 3, 4, 5, 6, 7, 8 | VA defined based on factors including military service history, disability rating and income level to identify veterans to determine enrolment priority; 1 is the highest priority [https://www.va.gov/health-care/eligibility/priority-groups/] | Most recent available |
| Nursing home use | 0/1 | 1 = Any nursing home or long-term care indicated on an inpatient admission or place of disposition | During 2 years prior to and on date of specimen collection date for SARS-CoV-2 lab test |
| Health and Human Services (HHS) region | Region 1<br>Region 2<br>Region 3<br>Region 4<br>Region 5<br>Region 6<br>Region 7<br>Region 8<br>Region 9<br>Region 10 | Region 1: (state abbreviation) CT, ME, NH, RI, VT<br>Region 2: NJ, NY<br>Region 3: DE, DC, MD, PA, VA, WV<br>Region 4: AL, FL, GA, KY, MS, NC, SC, TN<br>Region 5: IL, IN, MI, MN, OH, WI | Most recent available value based on location of patient's residence |

| | | | |
|---|---|---|---|
| | | Region 6: AR, LA, NM, OK, TX<br>Region 7: IA, KS, MO, NE<br>Region 8: CO, MT, ND, SD, UT, WY<br>Region 9: AZ, CA, HI, NV<br>Region 10: AK, ID, OR, WA | |
| Homeless | 0/1 | 1= ICD-10 code Z59.0 or Z59.1<br>on any inpatient or outpatient record | During 2 years prior to specimen collection date for SARS-CoV-2 lab test |
| Low Income | 0/1 | 1 = income less than 12,760, but not missing income<br>0 = missing or income greater than equal to 12760 | During 2 years prior to specimen collection date for SARS-CoV-2 lab test |
| Quan-CCI | Numeric | Using ICD-10 codes from any inpatient or outpatient record, computed Charlson Comorbidity Index, Quan's version [Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical Care 2005; 43(11):1130-1139. DOI: 10.1097/01.mlr.0000182534.19832.83] | During 2 years prior to and on date of specimen collection date for SARS-CoV-2 lab test |
| BMI | Normal<br>Overweight/obese<br>Missing | Normal: BMI less than 26<br>Overweight/obese: BMI greater than or equal to 26 | During 2 years prior to and on date of specimen collection date for SARS-CoV-2 lab test |
| Comorbidities | | All comorbidities listed below have 1 inpatient or 2 outpatient records with the corresponding ICD-10 code | During 2 years prior to and on date of specimen collection date for SARS-CoV-2 lab test |
| Asthma | 0/1 | ICD-10 code J45*<br>ICD-10 code J44.9*<br>ICD-10 code J67.8* | |
| Cancer | 0/1 | Charlson condition definitions using ICD-10 codes | |
| Cancer metastatic | 0/1 | Charlson condition definitions using ICD-10 codes | |
| Coronary artery disease | 0/1 | ICD-10 code I 25* | |

| | | | |
|---|---|---|---|
| Congestive heart failure | 0/1 | Charlson condition definitions using ICD-10 codes | |
| Chronic kidney disease | 0/1 | ICD-10 code N18* | |
| Chronic obstructive pulmonary disease | 0/1 | Charlson condition definitions using ICD-10 codes | |
| Cardiovascular disease | 0/1 | Charlson condition definitions using ICD-10 codes | |
| Dementia | 0/1 | Charlson condition definitions using ICD-10 codes | |
| Diabetes mellitus with complications | 0/1 | Charlson condition definitions using ICD-10 codes | |
| Diabetes mellitus without complications | 0/1 | Charlson condition definitions using ICD-10 codes | |
| Dyslipidemia | 0/1 | ICD-10 code E78.5* | |
| HIV | 0/1 | Charlson condition definitions using ICD-10 codes | |
| Hypertension | 0/1 | ICD-10 code H35.03<br>ICD-10 code I10*<br>ICD-10 code I11*<br>ICD-10 code I12*<br>ICD-10 code I13*<br>ICD-10 code I15*<br>ICD-10 code I16<br>ICD-10 code I67.4 | |
| Liver disease, mild | 0/1 | Charlson condition definitions using ICD-10 codes | |
| Liver disease, moderate/severe | 0/1 | Charlson condition definitions using ICD-10 codes | |
| Myocardial infarction (history) | 0/1 | Charlson condition definitions using ICD-10 codes | |
| Para/hemiplegia | 0/1 | Charlson condition definitions using ICD-10 codes | |
| Peptic ulcer disease | 0/1 | Charlson condition definitions using ICD-10 codes | |
| Peripheral vascular disease | 0/1 | Charlson condition definitions using ICD-10 codes | |
| Rheumatoid arthritis | 0/1 | Charlson condition definitions using ICD-10 codes | |

| | | | |
|---|---|---|---|
| Renal disease | 0/1 | Charlson condition definitions using ICD-10 codes | |
| Atrial fibrillation | 0/1 | ICD-10 code I48.0<br>ICD-10 code I48.11<br>ICD-10 code I48.19<br>ICD-10 code I48.21<br>ICD-10 code I48.91 | |
| Anaphylaxis (history) | 0/1 | ICD-10 code Z87.892 | |
| Arthritis | 0/1 | ICD-10 code M15* through M19* | |
| Bleeding diathesis | 0/1 | ICD-10 code D69.9 | |
| Brocheostasis | 0/1 | ICD-10 code J47* | |
| Depression | 0/1 | ICD-10 code F33* | |
| Down Syndrome | 0/1 | ICD-10 code Q90* | |
| Embolism (history) | 0/1 | ICD-10 code I82*<br>ICD-10 code I74*<br>ICD-10 code I26* | |
| Falls (history) | 0/1 | ICD-10 code W19* | |
| Gout | 0/1 | ICD-10 code M1A* | |
| Hepatitis B | 0/1 | ICD-10 code B19.1* | |
| Hepatitis C | 0/1 | ICD-10 code B19.2* | |
| Hyperlipidemia | 0/1 | ICD-10 code E78.2<br>ICD-10 code E78.41<br>ICD-10 code E78.49<br>ICD-10 code E78.5 | |
| Hypersensitivity pneumonitis | 0/1 | ICD-10 code J67* | |
| Interstitial lung disease | 0/1 | ICD-10 code J80*<br>ICD-10 code J81*<br>ICD-10 code J82*<br>ICD-10 code J84* | |
| Impaired mobility | 0/1 | ICD-10 code Z74.01<br>ICD-10 code Z74.09 | |
| Musculoskeletal disorder | 0/1 | ICD-10 code M00* through M99* | |
| Mycoses | 0/1 | ICD-10 code B35* through B49* | |
| Obesity | 0/1 | ICD-10 code E66* | |
| Paranoia | 0/1 | ICD-10 code F22*<br>ICD-10 code F60* | |
| Parkinson's | 0/1 | ICD-10 code G20* | |
| Pregnancy (history) | 0/1 | ICD-10 code Z33* | |
| Drug-induced anaphylaxis | 0/1 | ICD-10 code Z88* | |

| | | | |
|---|---|---|---|
| Sickle cell disease | 0/1 | ICD-10 code D57* | |
| Solid organ transplant recipient | 0/1 | ICD-10 code Z94* | |
| Stroke / transient ischemic attach | 0/1 | ICD-10 code I63*<br>ICD-10 code G45* | |
| Urinary tract infection | 0/1 | ICD-10 code N39.0 | |
| Immuno-comp-romised | 0/1 | ICD-10 code B20*<br>ICD-10 code B59*<br>ICD-10 code B97.3*<br>ICD-10 code D47.Z1*<br>ICD-10 code D70*<br>ICD-10 code D71*<br>ICD-10 code D72*<br>ICD-10 code D73*<br>ICD-10 code D76*<br>ICD-10 code D80*<br>ICD-10 code D81*<br>ICD-10 code D82*<br>ICD-10 code D83*<br>ICD-10 code D84*<br>ICD-10 code D89*<br>ICD-10 code M05*<br>ICD-10 code M06*<br>ICD-10 code M07*<br>ICD-10 code M08*<br>ICD-10 code M30*<br>ICD-10 code M31*<br>ICD-10 code M32*<br>ICD-10 code M33*<br>ICD-10 code M34*<br>ICD-10 code M35.0*<br>ICD-10 code M35.9*<br>ICD-10 code Q89.0*<br>ICD-10 code T45.1X1<br>ICD-10 code Z21*<br>ICD-10 code Z48.2*<br>ICD-10 code Z51.0*<br>ICD-10 code Z51.1*<br>ICD-10 code Z94* | |
| Vaccination status | None<br>Partial<br>Full | None: until first vaccination date<br>Partial: from 7 days after the first vaccination date and before the second vaccination date<br>Full: from 7 days after the second vaccination date | Determined at the specimen collection date for SARS-CoV-2 lab test during the study period (December 14, 2020 to March 7, 2021) |
| Vaccine manufacturer | None<br>Moderna<br>Pfizer | None: no vaccination recorded<br>Moderna: CPT codes 91301, 0011A, 0012A or vaccination name<br>Pfizer: CPT codes 91300, 0001A, 0002A or | Determined at date of first vaccination during the study period (December 14, 2020 to March 7, 2021) |

| | | | |
|---|---|---|---|
| | | vaccination name | |
| Month of SARS-CoV-2 test | 2020-Dec<br>2021-Jan<br>2021-Feb<br>2021-Mar | Month of the specimen collection date for SARS-CoV-2 lab test | Study period (December 14, 2020 to March 7, 2021) |
| Care setting for SARS-CoV-2 test | ED/At Admission<br>Outpatient | ED/At Admission: Specimen collection date for SARS-CoV-2 lab test on the same date as ED visit or during an inpatient stay<br>Outpatient: Specimen collection date for SARS-CoV-2 lab test on the same date as outpatient or urgent care visit | Assessed from specimen collection dates and visit dates during the study period (December 14, 2020 to March 7, 2021) |
| Health and Human Services (HHS) region | Region 1<br>Region 2<br>Region 3<br>Region 4<br>Region 5<br>Region 6<br>Region 7<br>Region 8<br>Region 9<br>Region 10 | Region 1: (state abbreviation) CT, ME, NH, RI, VT<br>Region 2: NJ, NY<br>Region 3: DE, DC, MD, PA, VA, WV<br>Region 4: AL, FL, GA, KY, MS, NC, SC, TN<br>Region 5: IL, IN, MI, MN, OH, WI<br>Region 6: AR, LA, NM, OK, TX<br>Region 7: IA, KS, MO, NE<br>Region 8: CO, MT, ND, SD, UT, WY<br>Region 9: AZ, CA, HI, NV<br>Region 10: AK, ID, OR, WA | Most recent available value based on location of patient residency |
| Homeless | 0/1 | 1= ICD-10 code Z59.0 or Z59.1<br>on any inpatient or outpatient record | During 2 years prior to specimen collection date for SARS-CoV-2 lab test |
| Low income | 0/1 | 1 = income less than 12,760, but not missing income<br>0 = missing or income greater than equal to 12760 | During 2 years prior to specimen collection date for SARS-CoV-2 lab test |
| Quan-CCI | Numeric | Using ICD-10 codes from any inpatient or outpatient record, computed Charlson Comorbidity Index, Quan's version [REF Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding | During 2 years prior to and on date of specimen collection date for SARS-CoV-2 lab test |

| | | | |
|---|---|---|---|
| | | algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical Care 2005; 43(11):1130-1139. DOI: 10.1097/01.mlr.0000182534.19832.83] | |
| BMI | Normal<br>Overweight/ obese<br>Missing | Normal: BMI less than 26<br>Overweight/obese: BMI greater than or equal to 26 | During 2 years prior to and on date of specimen collection date for SARS-CoV-2 lab test |
| CAN Score | | Score to identify patients at highest risk of hospitalization and mortality. As indicated in VHA data. If missing, the score is assumed to be zero.[ https://www.va.gov/HEALTHCAREEXCELLENCE/about/organization/examples/care-assessment-needs.asp] | Most recent CAN score during 2 years prior to and on date of specimen collection date for SARS-CoV-2 lab test |
| Mortality-1 year | Percentage of probability | Measurement of risk of mortality in next year | |
| Mortality-90 days | Percentage of probability | Measurement of risk of mortality in the next 90 days | |
| Event-1 year | Percentage of probability | Measurement of risk of any visit or event in the next year | |
| Event-90 days | Percentage of probability | Measurement of risk of any visit or event in the next 90 days | |
| Hospitalization-1 year | Percentage of probability | Measurement of risk of a hospitalization in the next year | |
| Hospitalization-90 days | Percentage of probability | Measurement of risk of a hospitalization in the next 90 days | |
| COVID-19 symptoms | | Symptoms as indicated from a combination of text search on inpatient admissions, ICD-10 codes, or as indicated in the COVID Domain | +/- 14 days around and including the COVID-19 lab test specimen date. |
| Any | 0/1 | Any one of the listed symptoms | |
| None | 0/1 | Missing all of the listed symptoms | |
| Fever | 0/1 | ICD-10 code R50.9*<br>COVID domain variable fever30d | |
| Shortness of breath | 0/1 | ICD-10 code R06.02*<br>ICD-10 code R06.0* | |

| | | | |
|---|---|---|---|
| | | ICD-10 code R09.02*<br>COVID domain variable dyspnea30d | |
| Cough | 0/1 | ICD-10 code R05*<br>COVID domain variable cough30d | |
| Loss of taste/smell | 0/1 | ICD-10 code R43.9*<br>ICD-10 code R43.8*<br>ICD-10 code R43.1*<br>ICD-10 code R43*<br>COVID domain variable lossoftaste30d | |
| Chills | 0/1 | ICD-10 code R68.83*<br>ICD-10 code R68.89*<br>COVID domain variable chills30d | |
| Diarrhea | 0/1 | ICD-10 code R19.7*<br>COVID domain variable diarrhea30d | |
| Sore throat | 0/1 | ICD-10 code J02.8*<br>ICD-10 code J02.9*<br>COVID domain variable sorethroat30d | |
| Myalgia | 0/1 | ICD-10 code M79.1*<br>COVID domain variable myalgia30d | |
| Vaccination (other pathogens) | | Other pathogen vaccinations identified by text search or CPT code (listed below) | The year prior to the specimen collection date for SARS-CoV-2 lab test |
| Influenza (2019/20 season) | 0/1 | CPT Code between 90655 and 90659, Q2034 and Q2039<br>CPT Code 90662 | |
| Influenza (2020/21 season) | 0/1 | CPT Code between 90655 and 90659, Q2034 and Q2039<br>CPT Code 90662 | |
| Abbreviations: BMI, body mass index; CAN Score, care assessment needs score; CPT, Current Procedural Terminology; ED, emergency department; HHS, Health and Human Services; International Classification of Diseases 10th Revision; VHA, Veterans Health Administration. | | | |

**Supplemental Table 2**. Vaccine Effectiveness Against Laboratory Confirmed SARS-CoV-2 Infection Among Patients with COVID-19 Symptoms[a]

| | VE, % (95%CI) | | | |
|---|---|---|---|---|
| | Full vs. no vaccination | | Partial vs. no vaccination | |
| | Unadjusted | Adjusted[b] | Unadjusted | Adjusted[b] |
| Overall | 93 (90, 95) | 91 (87, 93) | 52 (46, 57) | 43 (36, 50) |
| Age, y | | | | |
| 18-64 | 90 (77, 96) | 89 (73, 95) | 40 (22, 54) | 31 (10, 48) |
| ≥65 | 89 (84, 92) | 88 (83, 91) | 43 (35, 49) | 42 (33, 49) |
| 18-79 | 90 (85, 93) | 89 (85, 93) | 42 (33, 49) | 40 (31, 47) |
| ≥80 | 88 (77, 93) | 88 (79, 94) | 44 (29, 56) | 38 (21, 52) |
| VHA defined priority group | | | | |
| 1-4 | 91 (85, 95) | 93 (87, 96) | 43 (31, 52) | 45 (34, 55) |
| 5-6 | 86 (76, 92) | 86 (77, 92) | 45 (33, 55) | 44 (31, 55) |
| 7-8 | 83 (70, 90) | 86 (76, 92) | 34 (18, 46) | 32 (16, 45) |
| Race or ethnic group | | | | |
| Black | 94 (85, 97) | 94 (85, 98) | 31 (13, 45) | 31 (13, 45) |
| Hispanic | 93 (52, 99) | 94 (54, 99) | 29 (-21, 58) | 16 (-44, 52) |
| White | 87 (81, 91) | 86 (80, 90) | 48 (40, 55) | 43 (34, 51) |
| Other | 96 (68, 99) | 93 (49, 99) | 47 (12, 68) | 37 (-6, 63) |
| Sex | | | | |
| Female | 77 (25, 93) | 68 (-6, 90) | 59 (21, 79) | 41 (-16, 70) |
| Male | 90 (86, 93) | 88 (84, 92) | 42 (35, 48) | 42 (35, 48) |
| Urban-rural | | | | |
| Rural | 88 (78, 94) | 87 (77, 93) | 46 (34, 57) | 41 (26, 53) |
| Urban | 90 (86, 93) | 89 (84, 92) | 40 (31, 48) | 41 (32, 49) |
| BMI | | | | |
| Normal | 95 (91, 97) | 95 (89, 97) | 55 (45, 63) | 48 (37, 58) |
| Obese | 82 (66, 90) | 83 (68, 91) | 31 (9, 47) | 39 (20, 54) |
| Missing | 84 (76, 90) | 84 (75, 89) | 37 (26, 47) | 33 (21, 44) |
| Underlying medical conditions | | | | |
| Cancer | 79 (58, 89) | 77 (56, 88) | 37 (13, 55) | 37 (11, 55) |
| Congestive heart failure | 77 (60, 87) | 76 (58, 87) | 43 (24, 57) | 42 (23, 57) |
| Chronic kidney disease | 88 (79, 94) | 88 (78, 94) | 40 (23, 53) | 43 (27, 56) |
| Diabetes mellitus | 91 (86, 95) | 92 (86, 95) | 47 (37, 55) | 45 (34, 54) |
| Hypertension | 88 (83, 92) | 87 (82, 91) | 47 (38, 54) | 42 (32, 50) |
| Immuno-compromised | 82 (71, 88) | 83 (72, 89) | 28 (11, 42) | 34 (18, 47) |

Abbreviations: BMI, body mass index; VE, vaccine effectiveness.
[a]See Supplemental Table 1 for definitions of variables in this table.
[b]The adjusted variables include the following: age, BMI, cancer, congestive heart failure, chronic kidney disease, diabetes mellitus, hypertension, immunocompromised, VA priority level, race, sex,

rurality.

**Supplemental Table 3**. Vaccine Effectiveness Against Laboratory Confirmed SARS-CoV-2 Infection, Utilizing VA+CMS Data[a,b]

| | VE, % (95%CI) | | | |
|---|---|---|---|---|
| | Full vs. no vaccination | | Partial vs. no vaccination | |
| | Unadjusted | Adjusted[c] | Unadjusted | Adjusted[c] |
| Overall | 87 (83, 89) | 87 (83, 89) | 43 (37, 48) | 42 (36, 48) |
| Age, y | | | | |
| 18-64 | 89 (77, 95) | 90 (79, 95) | 44 (27, 57) | 43 (26, 57) |
| ≥65 | 88 (84, 91) | 88 (84, 91) | 47 (41, 53) | 46 (39, 51) |
| 18-79 | 87 (82, 91) | 86 (81, 90) | 38 (30, 46) | 37 (27, 45) |
| ≥80 | 81 (12, 96) | 82 (6, 97) | -31 (-125, 24) | -47 (-163, 18) |
| VHA defined priority group | | | | |
| 1-4 | 87 (79, 92) | 87 (80, 92) | 52 (42, 61) | 51 (40, 60) |
| 5-6 | 84 (72, 90) | 83 (71, 90) | 44 (30, 56) | 45 (30, 56) |
| 7-8 | 85 (69, 93) | 83 (64, 92) | 22 (-3, 41) | 24 (-2, 43) |
| Race or ethnic group | | | | |
| Black | 92 (82, 96) | 91 (81, 96) | 37 (16, 52) | 30 (7, 47) |
| Hispanic | 100 (100, 100) | 53 (-188, 92) | 55 (-26, 84) | 64 (-11, 88) |
| White | 83 (78, 88) | 84 (78, 88) | 44 (36, 51) | 46 (39, 53) |
| Other | 61 (-278, 96) | 45 (-605, 96) | 55 (-31, 84) | 69 (-4, 91) |
| Sex | | | | |
| Female | 100 (100, 100) | 56 (-325, 95) | 66 (-26, 91) | 61 (-55, 90) |
| Male | 87 (83, 90) | 87 (83, 90) | 42 (36, 48) | 41 (34, 46) |
| Urban-rural | | | | |
| Rural | 87 (76, 93) | 87 (76, 93) | 45 (30, 57) | 46 (31, 58) |
| Urban | 84 (78, 88) | 83 (78, 88) | 38 (30, 45) | 36 (27, 44) |
| BMI | | | | |
| Normal | 29 (-10, 55) | 42 (8, 63) | 78 (47, 91) | 81 (54, 92) |
| Obese | 29 (15, 40) | 27 (12, 39) | 84 (75, 90) | 83 (74, 89) |
| Missing | 54 (43, 63) | 51 (40, 61) | 89 (82, 93) | 88 (80, 93) |
| Underlying medical conditions | | | | |
| Cancer | 100 (100, 100) | 41 (-236, 90) | 49 (-10, 76) | 66 (18, 86) |
| Congestive heart failure | 67 (10, 88) | 71 (17, 90) | 47 (8, 70) | 49 (9, 72) |
| Chronic kidney disease | 86 (53, 96) | 87 (56, 96) | 51 (23, 69) | 47 (15, 67) |
| Diabetes mellitus | 90 (81, 94) | 89 (80, 94) | 36 (20, 49) | 34 (17, 48) |
| Hypertension | 85 (78, 89) | 85 (79, 90) | 35 (24, 45) | 36 (24, 45) |
| Immuno- | 65 (32, 82) | 67 (35, 83) | 33 (6, 52) | 37 (11, 55) |

| | | | | |
|---|---|---|---|---|
| compromised | | | | |

Abbreviations: BMI, body mass index; CMS, Centers for Medicare and Medicaid Services; ICD-10, International Classification of Diseases 10th Revision; VA, Veterans Affairs; VE, vaccine effectiveness.

[a]Since 2020, for VHA enrolled patients with Medicare who have either tested positive for SARS-Cov-2 at a VHA facility or who have a COVID-19 medical claim in Medicare (ICD-10 codes B97.29 [“Other coronavirus”] and U07.1 [“COVID-19”] diagnosis code in inpatient, skilled nursing facility, institutional outpatient, hospice, and carrier/Part B files), the VHA receives the patients’ Medicare data with a 4-5 week lag time [REF https://vaww.virec.research.va.gov/VACMS/Medicare/COVID19-Data.htm].

[b]See Supplemental Table 1 for definitions of variables in this table.

[c]The adjusted variables include the following: age, BMI, cancer, congestive heart failure, chronic kidney disease, diabetes mellitus, hypertension, immunocompromised, VA priority level, race, sex, rurality.